Aprea Therapeutics 2025 Q3 Earnings 21.4% Reduction in Net Loss

Aprea Therapeutics (APRE) reported fiscal 2025 Q3 earnings on Nov 12, 2025, with a 21.4% reduction in net loss compared to the prior year. The company narrowed losses to $0.47 per share and $2.97 million in net loss, reflecting improved cost management and a clear cash runway into Q4 2026. Guidance emphasized clinical milestones and capital efficiency, aligning with the CEO’s optimism about 2026 catalysts.

Revenue

Total revenue plummeted to $1,848, entirely derived from grant funding, a stark 99.5% decline from the $354,621 recorded in the same period last year. This collapse underscores the company’s reliance on non-recurring income and lack of commercial revenue streams.

Earnings/Net Income

Aprea Therapeutics narrowed losses to $0.47 per share in 2025 Q3, a 26.6% improvement from a $0.64 loss per share in 2024 Q3. Meanwhile, the net loss decreased to $-2.97 million, a 21.4% reduction from the $-3.78 million loss in 2024 Q3. The EPS improvement and reduced net loss indicate a positive trend in cost management and operational efficiency.

Price Action

The stock price of Aprea Therapeutics has edged down 1.56% during the latest trading day, has dropped 3.96% during the most recent full trading week, and has tumbled 14.29% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Aprea Therapeutics (APRE) shares on the date of quarterly earnings releases and holding for 30 days showed poor performance over the past three years. The APRE shares declined in the 30 days following the earnings release dates in Q1 2023, Q2 2023, and Q3 2025, with losses of 13.17%, 18.06%, and 15.62%, respectively. This indicates that this strategy did not yield positive returns for the entire three-year period.

CEO Commentary

Oren Gilad, Ph.D., President and CEO of Aprea Therapeutics, highlighted clinical progress in APR-1051 and ATRN-119 programs, noting 3/4 patients with stable disease in the 100 mg once-daily APR-1051 cohort and identification of the RP2D for ATRN-119. He emphasized the “differentiated DDR approach” and plans to explore combination therapies (e.g., radiation or checkpoint inhibitors) to expand clinical impact. Gilad expressed optimism about “value-creating clinical catalysts anticipated in 2026,” underscoring confidence in the pipeline’s potential to address unmet medical needs in gastrointestinal and gynecologic malignancies, as well as DDR-related cancers.

Guidance

The company confirmed a cash runway into Q4 2026, based on $13.7 million in cash and cash equivalents as of Q3 2025. Forward-looking guidance includes advancing APR-1051 to the 150 mg once-daily cohort in ACESOT-1051 and evaluating combination strategies for ATRN-119 post-RP2D determination. No explicit revenue or EPS guidance was provided, but the company reiterated focus on clinical milestones and capital efficiency.

Additional News

Aprea Therapeutics reported clinical updates in APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor). APR-1051 advanced to 150 mg QD after 3/4 patients showed stable disease at 100 mg QD, while ATRN-119 paused monotherapy enrollment to explore combination therapies post-RP2D identification. The company also highlighted a $13.7 million cash runway into Q4 2026, reinforcing its ability to fund operations through 2026. These developments align with the CEO’s emphasis on 2026 catalysts and DDR-focused pipeline expansion.